Retraction: Alpha-Fetoprotein Promoter-Driven Cre/LoxP-Switched RNA Interference for Hepatocellular Carcinoma Tissue-Specific Target Therapy (PLoS ONE (2013) 8:2 (e53072) DOI: 10.1371/journal.pone.0053072);Alpha-Fetoprotein Promoter-Driven Cre/LoxP-Switched RNA Interference for Hepatocellular Carcinoma Tissue-Specific Target Therapy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Peng, Yuan Fei ^a   Shi, Ying Hong ^a   Ding, Zhen Bin ^a   Zhou, Jian ^a   Qiu, Shuang Jian ^a   Hui, Bo ^a   Gu, Cheng Yu ^a   Yang, Hua ^a   Liu, Wei Ren ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AUTOPHAGY PROTEIN 5; BECLIN 1; CRE RECOMBINASE; MICRORNA; SHORT HAIRPIN RNA; SORAFENIB;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATG5 GENE; BECLIN 1 GENE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEASIBILITY STUDY; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOXP SITE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TISSUE SPECIFICITY; WESTERN BLOTTING;

EID: 84874529329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0295656     Document Type: Erratum

References (26)

1. Forner A, Llovet JM, Bruix J, (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
2. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
3. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK, (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67.
4. Chen SH, Zhaori G, (2011) Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 41: 221-232.
5. Petrocca F, Lieberman J, (2011) Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29: 747-754.
6. Marquardt JU, Galle PR, Teufel A, (2012) Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 56: 267-275.
7. Xu C, Lee SA, Chen X, (2011) RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov 6: 106-115.
8. Bora RS, Gupta D, Mukkur TK, Saini KS, (2012) RNA interference therapeutics for cancer: Challenges and opportunities (Review). Mol Med Report 6: 9-15.
9. Gilmore IR, Fox SP, Hollins AJ, Akhtar S, (2006) Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 3: 147-145.
10. Johnson PJ, (1999) Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 14 Suppl: S32-36.
11. Ido A, Nakata K, Kato Y, Nakao K, Murata K, et al. (1995) Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 55: 3105-3109.
12. Kaneko S, Tamaoki T, (2001) Gene therapy vectors harboring AFP regulatory sequences. Preparation of an adenoviral vector. Mol Biotechnol 19: 323-330.
13. Hirano T, Kaneko S, Kaneda Y, Saito I, Tamaoki T, et al. (2001) HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Ther 8: 80-83.
14. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, et al. (1997) In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 57: 461-465.
15. Mao CY, Hua HJ, Chen P, Yu DC, Cao J, et al. (2009) Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 8: 282-287.
16. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, et al. (2002) E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5: 627-634.
17. Sakuma T, Barry MA, Ikeda Y, (2012) Lentiviral vectors: basic to translational. Biochem J 443: 603-618.
18. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, et al. (2011) Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7: 1159-1172.
19. Li Y, Tang Y, Ye L, Liu B, Liu K, et al. (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129: 43-51.
20. Li Y, Tang Z-Y, Hou J-X, (2012) Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 9: 32-43.
21. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, et al. (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7: 630-636.
22. Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, et al. (2008) Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 68: 9167-9175.
23. Peng Y, Zheng M, Feng B, Chen X, Yu B, et al. (2008) Hyperthermic CO2 pneumoperitoneum induces apoptosis in human colon cancer cells through Bax-associated mitochondrial pathway. Oncol Rep 19: 73-79.
24. Li Y, Tian B, Yang J, Zhao L, Wu X, et al. (2004) Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 130: 460-468.
25. Yang PL, Althage A, Chung J, Chisari FV, (2002) Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 99: 13825-13830.
26. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, et al. (2004) Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 11: 675-682.